CDKN1B is altered in 1.96% of malignant solid tumor patients [3].

CDKN1B is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain CDKN1B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [4].

CDKN1B is altered in 2.73% of breast carcinoma patients [3].

CDKN1B is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1B status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

CDKN1B is altered in 1.78% of non-hodgkin lymphoma patients [3].

CDKN1B is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN1B status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDKN1B is altered in 1.74% of colorectal carcinoma patients [3].

CDKN1B is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1B status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

CDKN1B is altered in 18.98% of germ cell tumor patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN1B is altered in 3.2% of bladder carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 2.19% of ovarian carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 2.27% of anaplastic astrocytoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 1.57% of histiocytic and dendritic cell neoplasm patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN1B status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDKN1B is altered in 1.51% of melanoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 1.72% of lymphoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 0.98% of head and neck carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 1.13% of gastric carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN1B is altered in 1.24% of non-small cell lung carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 1.34% of sarcoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 0.61% of pancreatic carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

CDKN1B is altered in 1.17% of esophageal carcinoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDKN1B is altered in 1.1% of glioblastoma patients [3].

CDKN1B is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].